Resistance to vemurafenib can be reversible after treatment interruption

Medicine (United States)

Volumn 93, Issue 27, 2014, Pages

  Mackiewicz Wysocka, Małgorzata ^a   Krokowicz, Łukasz ^a   Kocur, Jacek ^b   Mackiewicz, Jacek ^a,b,c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b GREATER POLAND CANCER CENTRE   (Poland)

^c Malgorzata Medical Center   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; B RAF KINASE; CARBOPLATIN; DACARBAZINE; IPILIMUMAB; LACTATE DEHYDROGENASE; PACLITAXEL; VEMURAFENIB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CASE REPORT; CLINICAL OBSERVATION; COMPUTER ASSISTED TOMOGRAPHY; ELECTROCORTICOGRAPHY; FEMALE; GENE MUTATION; HUMAN; IN-TRANSIT METASTASIS; KIDNEY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER; LIVER METASTASIS; LUNG; LUNG METASTASIS; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; POLAND; REIMBURSEMENT; RETREATMENT; SOFT TISSUE METASTASIS; SPLEEN; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84919346055     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000157     Document Type: Article

References (11)

1. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380: 358-365.
2. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
3. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell. 2011; 19: 11-15.
4. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer. 2013; 49: 1297-1304.
5. Romano E, Pradervand S, Paillusson A, et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res. 2013; 19: 5749-5757.
6. Seghers AC, Wilgenhof S, Lebbé C, et al. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res. 2012; 22: 466-472.
7. Abusaif S, Jradi Z, Held L, et al. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma. Melanoma Res. 2013. [Epub ahead of print]
8. Das Thakur M, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013; 494: 251-255.
9. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulation. Cell. 2010; 141: 69-80.
10. Kurata T, Tamura K, Kaneda H, et al. Effect of re-treatment with gefitinib ("Iressa, " ZD1839) after acquisition of resistance. Ann Oncol. 2004; 15: 173-174.
11. Yano S, Nakataki E, Ohtsuka S, et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res. 2005; 15: 107-111.